Abstract
Transmissible spongiform encepahalopathies (TSEs) are fatal diseases that damage the central nervous system. TSEs are unique in that they may be inherited, infectious or spontaneous. The central pathogenic agent is thought to be a conformationally distinct form (PrPSc) of the endogenous prion protein(PrPc), which is high in beta-sheet content and is resistant to proteases; infectivity is thought to involve formation of PrPSc via imprinting of abnormal conformation on the normal form of the protein (PrPc) by seeds of PrPSc. A number of compounds found to inhibit the conversion of PrPc to PrPSc have been proposed as therapeutics to halt TSEs.
Keywords: spongiform encephalopathies, prions, beta-sheet, proline peptides
Protein & Peptide Letters
Title: Experimental Approaches to Tse Prevention Via Inhibition of Prion Formation
Volume: 11 Issue: 3
Author(s): Galatia Politopoulou
Affiliation:
Keywords: spongiform encephalopathies, prions, beta-sheet, proline peptides
Abstract: Transmissible spongiform encepahalopathies (TSEs) are fatal diseases that damage the central nervous system. TSEs are unique in that they may be inherited, infectious or spontaneous. The central pathogenic agent is thought to be a conformationally distinct form (PrPSc) of the endogenous prion protein(PrPc), which is high in beta-sheet content and is resistant to proteases; infectivity is thought to involve formation of PrPSc via imprinting of abnormal conformation on the normal form of the protein (PrPc) by seeds of PrPSc. A number of compounds found to inhibit the conversion of PrPc to PrPSc have been proposed as therapeutics to halt TSEs.
Export Options
About this article
Cite this article as:
Politopoulou Galatia, Experimental Approaches to Tse Prevention Via Inhibition of Prion Formation, Protein & Peptide Letters 2004; 11 (3) . https://dx.doi.org/10.2174/0929866043407192
DOI https://dx.doi.org/10.2174/0929866043407192 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Involvement of L-Carnitine in Cellular Metabolism: Beyond Acyl-CoA Transport
Mini-Reviews in Medicinal Chemistry Silencing of Disease-related Genes by Small Interfering RNAs
Current Molecular Medicine Enzyme / Abzyme Prodrug Activation Systems: Potential Use in Clinical Oncology
Current Pharmaceutical Design Molecular Foundations for Personalized Therapy in Prostate Cancer
Current Drug Targets Insights Into Effects of Ellagic Acid on the Nervous System: A Mini Review
Current Pharmaceutical Design The Roles of Histone Demethylase UTX and JMJD3 (KDM6B) in Cancers: Current Progress and Future Perspectives
Current Medicinal Chemistry MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets Kinetic Study on the Effects of Extremely Low Frequency Electromagnetic Field on Catalase, Cytochrome P450 and Inducible Nitric Oxide Synthase in Human HaCaT and THP-1 Cell Lines
CNS & Neurological Disorders - Drug Targets Regenerative Potential of Mesenchymal Stem Cell-Derived Extracellular Vesicles
Current Molecular Medicine Editorial [Hot Topic:Drug Targets in Ageing and Age-Associated Diseases (Executive Editors: C. Caruso and E. Jirillo)]
Current Pharmaceutical Design Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Natural Polymeric Nanoparticles for Brain-Targeting: Implications on Drug and Gene Delivery
Current Pharmaceutical Design Scope of Lipid Nanoparticles in Neuroscience: Impact on the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Psychotropic Medications and the Treatment of Human Prion Diseases
CNS & Neurological Disorders - Drug Targets Druggability of Mortalin for Cancer and Neuro-Degenerative Disorders
Current Pharmaceutical Design Gamma-Secretase as a Pharmacological Target in Alzheimer Disease Research: When, Why and How?
Current Pharmaceutical Design 2´,3´-Dialdehyde of ATP, ADP, and Adenosine Inhibit HIV-1 Reverse Transcriptase and HIV-1 Replication
Current HIV Research Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets Genetic Engineering of AAV Capsid Gene for Gene Therapy Application
Current Gene Therapy Role of FK506 Binding Proteins in Neurodegenerative Disorders
Current Medicinal Chemistry